central nervous system diagnostic radiopharmaceuticals	used for	brain imaging
central nervous system diagnostic radiopharmaceuticals	labeled with	radioactive isotope
radioactive isotope	emits	gamma radiation
gamma radiation	detected by	PET scanner
PET scanner	measures	tracer uptake
tracer uptake	indicates	metabolic activity
metabolic activity	altered in	neurodegenerative disease
neurodegenerative disease	includes	Alzheimer disease
neurodegenerative disease	includes	Parkinson disease
neurodegenerative disease	includes	Huntington disease
central nervous system diagnostic radiopharmaceuticals	include	18F-FDG
18F-FDG	accumulates in	tumor cells
tumor cells	show	increased glucose metabolism
central nervous system diagnostic radiopharmaceuticals	include	11C-PiB
11C-PiB	binds to	amyloid plaques
amyloid plaques	present in	Alzheimer disease
central nervous system diagnostic radiopharmaceuticals	include	18F-AV45
18F-AV45	binds to	beta‑amyloid
beta‑amyloid	accumulates in	cerebral cortex
cerebral cortex	affected in	dementia
central nervous system diagnostic radiopharmaceuticals	include	18F-FDOPA
18F-FDOPA	used for	dopaminergic imaging
dopaminergic imaging	assesses	dopamine synthesis
dopamine synthesis	reduced in	Parkinson disease
central nervous system diagnostic radiopharmaceuticals	include	11C-CFT
11C-CFT	binds to	dopamine transporter
dopamine transporter	decreased in	Parkinson disease
central nervous system diagnostic radiopharmaceuticals	include	18F-FEPPA
18F-FEPPA	binds to	TSPO
TSPO	marker of	neuroinflammation
neuroinflammation	seen in	multiple sclerosis
central nervous system diagnostic radiopharmaceuticals	include	18F-DPA-714
18F-DPA-714	binds to	TSPO
TSPO	elevated in	traumatic brain injury
central nervous system diagnostic radiopharmaceuticals	include	18F-THK5351
18F-THK5351	binds to	tau protein
tau protein	aggregates in	frontotemporal dementia
frontotemporal dementia	subtype of	dementia
central nervous system diagnostic radiopharmaceuticals	include	18F-AV1451
18F-AV1451	binds to	tau aggregates
tau aggregates	present in	chronic traumatic encephalopathy
central nervous system diagnostic radiopharmaceuticals	include	18F-AV-1451
18F-AV-1451	used for	tau imaging
tau imaging	informs	disease progression
disease progression	predicts	functional decline
functional decline	leads to	caregiver burden
caregiver burden	increases	readmission risk
readmission risk	associated with	hospital stay length
hospital stay length	influenced by	imaging findings
imaging findings	guide	treatment planning
treatment planning	affects	medication choice
medication choice	impacts	adverse drug events
adverse drug events	increase	mortality risk
mortality risk	correlated with	disease severity
disease severity	measured by	clinical staging
clinical staging	refined by	imaging biomarkers
imaging biomarkers	improve	prognostic accuracy
prognostic accuracy	reduces	unnecessary interventions
unnecessary interventions	lower	healthcare costs
healthcare costs	affect	insurance coverage
insurance coverage	determines	patient access
patient access	influences	treatment adherence
treatment adherence	predicts	long‑term outcomes
long‑term outcomes	include	survival
survival	depends on	early detection
early detection	facilitated by	PET imaging
PET imaging	requires	radiopharmaceutical availability
radiopharmaceutical availability	limited by	production capacity
production capacity	constrained by	cyclotron availability
cyclotron availability	varies by	geographic region
geographic region	affects	patient wait times
patient wait times	correlate with	disease progression
disease progression	worsens	quality of life
quality of life	measured by	patient‑reported outcomes
patient‑reported outcomes	used in	clinical trials
clinical trials	evaluate	new radiopharmaceuticals
new radiopharmaceuticals	undergo	regulatory approval
regulatory approval	requires	safety data
safety data	includes	radiation dose
radiation dose	impacts	cumulative exposure
cumulative exposure	linked to	cancer risk
cancer risk	mitigated by	dose optimization
dose optimization	guided by	pharmacokinetics
pharmacokinetics	studied in	population subsets
population subsets	include	elderly patients
elderly patients	have	altered metabolism
altered metabolism	changes	tracer clearance
tracer clearance	affects	image quality
image quality	determines	diagnostic confidence
diagnostic confidence	influences	clinical decision
clinical decision	affects	surgical planning
surgical planning	improves	resection accuracy
resection accuracy	reduces	recurrence risk
recurrence risk	lowers	mortality
mortality	tracked in	epidemiologic studies
epidemiologic studies	inform	public health policy
public health policy	shapes	funding allocation
funding allocation	supports	research infrastructure
research infrastructure	enhances	diagnostic capabilities
diagnostic capabilities	expand	patient care options
